| 摘要 |
N-(Substituted alkyl)-2-amino-pyridine derivatives (including diaza analogues) of formula (I) and their salts are new. A = fibrinogen antagonist template; W = linking group of formula -(CHRg)a-U-(CHRg)b-V-; Q1-Q4 = N or CRy, provided that not more than one is N; R' = H, alkyl, cycloalkyl, cycloalkylalkyl, Ar or Ar-alkyl; Rg = H, alkyl, Het, Het-alkyl, cycloalkyl, cycloalkylalkyl, Ar or Ar-alkyl; Rk = Rg, CORg or COORg; Ri = Rg, Het-U'-alkyl, Het-alkyl-U'-alkyl, cycloalkyl-U'-alkyl, cycloalkyl-alkyl-U'-alkyl, Ar-U'-alkyl or Ar-alkyl-U'-alkyl; Ry = H, halo, ORg, SRg, CN, NRgRk, NO2, CF3, CF3S(O)r-, COORg, CORg or CON(Rg)2; or alkyl (optionally substituted by halo, ORg, SRg, CN, NRgR", NO2, CF3, R'S(O)3-, COORg, CORg or CON(Rg)2); U,V = absent, CO, C(Rg)2, C=C(Rg)2, S(O)c, O, NRg, CRgORg, CRg(ORk)C(Rg)2, C(Rg)2CRg(ORk), COC(Rg)2, C(Rg)2CO, CONRi, NRiCO, OCO, COO, CSO, OCS, CSNRg, NRgCS, S(O)2NRg, NRgS(O)2N=N, NRgNRg, NRgC(Rg)2, C(Rg)2O, OC(Rg)2, CRg=CRg, C?=C, Ar or Het; N.B. U', R", Ar and Het are not defined; a =0-3; b, c, r = 0-2; u = 0 or 1; alkyl moieties have 1-6C and cycloalkyl moieties have 3-7C. |
